فعالية وأمان استعمال سكروز الحديد الوريدي في معالجة فقر الدم عند مرضى التحال الدموي المزمن

Authors

  • عبد الفتاح عباس

Abstract

أجريت هذه الدراسة في وحدة التحال الدموي في مشفى الأسد الجامعي باللاذقية وشملت 41 مريضاً يخضعون للتحال الدموي المزمن لفترة تزيد عن ستة أشهر ويعالجون بهرمون الإريتروبوئيتين منذ أربعة أشهر على الأقل دون أن يتجاوز مستوى الخضاب عندهم 10غ/دل وكان مستوى الفيريتين عندهم عند بداية الدراسة أقل من 100مكغ/ل (نقص حديد مطلق).

أعطي جميع مرضى الدراسة سكروز الحديد بالحقن الوريدي البطيء بجرعة 100ملغ مرة واحدة أسبوعياً ولمدة ثمانية أسابيع.

وبنتيجة الدراسة ارتفع متوسط الخضاب عندهم من 7.28 إلى 10.36 (p<0.001)  كما ارتفع متوسط الفيريتين من 76.36 إلى 460.53 (p<0.0001) ولم تظهر أية تفاعلات تحسسية عند أي من مرضى الدراسة مما يظهر فعالية هذا العلاج وأمانه عند مرضى التحال الدموي المزمن.

 

This study was carried out in the Hemolialysis Unit at AL-Assad University Hospital, Lattakia, and included 41 patients on chronic hemodialysis for more than 6 months, treated by erythropoietin for 4 months at least with hemoglobin concentration less than 10 g\dl and serum ferritin less than 100  (absolute iron deficiency) at the beginning of the study.

All patients received iron sucrose (100 mg\once per week for 8 weeks) by slow intravenous injection.

We found out that mean hemoglobin level increased from 7.28 to 10.36 (p< 0.001) and mean serum ferritin level increased from 76.36 to 460.53 (p< 0.0001) and none of the patients developed hypersensitivity reactions.

We conclude that iron sucrose is effective and safe in hemodialysis patients.

Downloads

Published

2019-01-17

How to Cite

1.
عباس عا. فعالية وأمان استعمال سكروز الحديد الوريدي في معالجة فقر الدم عند مرضى التحال الدموي المزمن. Tuj-hlth [Internet]. 2019Jan.17 [cited 2024Apr.28];30(3). Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/6540

Issue

Vol. 30 No. 3 (2008): العلوم الصحية

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Most read articles by the same author(s)